CTTQ
Status and phase
Conditions
Treatments
About
TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against Human Epidermal Growth Factor Receptor 2 (HER2), an enzyme-cleavable linker, and a topoisomerase I inhibitor payload, which combine the ability of antibodies to specifically target tumour cells with the highly potent killing activity of drugs with payloads too toxic for systemic administration. This is a Phase 1/Phase 2 study to evaluate the effectiveness, safety, pharmacokinetics (PK) and anti-drug antibody (ADA) of TQB2102 for injection in subjects with HER2-expressing relapsed/metastatic breast cancer.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Concomitant disease and medical history:
Tumor related symptoms and treatment:
Study treatment related: people who are known to be allergic to the study drug or its excipients, or to humanized monoclonal antibody products;
Patients who participated in and used other anti-tumor clinical trials within 4 weeks before the first medication;
In the judgment of the investigator, there is a situation that seriously endangers the safety of the subjects or affects the completion of the study.
Primary purpose
Allocation
Interventional model
Masking
150 participants in 1 patient group
Loading...
Central trial contact
Qingyuan Zhang, Doctor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal